skip to main content

Endometrial Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersEndometrial CancerSCE Medical Oncology

Molecular testing of a resected endometrial carcinoma finds a pathogenic POLE exonuclease-domain mutation and abnormal p53 immunohistochemistry, with intact mismatch-repair proteins. How should this multiple-classifier tumour be assigned for molecular risk classification under the 2025 ESGO-ESTRO-ESP framework?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Classify as POLE-mutated because POLEmut is hierarchical over coincident p53 abnormality

Option B is correct: POLEmut-p53abn multiple-classifier tumours are assigned to the POLE-mutated group. Option A applies the adverse p53 category without the required hierarchy. Option E invents cancellation into NSMP. Option C contradicts intact MMR, and option D discards clinically meaningful molecular classification.

Reference: ESGO-ESTRO-ESP 2025 endometrial cancer guideline. https://guidelines.esgo.org/media/2025/09/ESGO-ESTRO-ESP-Guidelines-for-EC_-LO-July-2025.pdf